National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor

Rapid Review

Commenced Completed Outcome
21 Sep 2012 12 Oct 2012 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.